Stock Events

Stock Events

Scynexis 

$0.88
0
-$0-0.43% Today

Statistics

Day High
0.88
Day Low
0.84
52W High
-
52W Low
-
Volume
274,939
Avg. Volume
-
Mkt Cap
36.8M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2025
Q4 2025
Next
-0.2
-0.05
0.1
0.25
Expected EPS
-0.126667
Actual EPS
N/A

Financials

-568.29%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
7.49MRevenue
-42.58MNet Income

Analyst Ratings

$3.00Average Price Target
The highest estimate is 3.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SCYX.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global pharmaceutical company that competes with Scynexis in the development of antifungal and antibacterial drugs.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is involved in the development of anti-infective drugs, directly competing with Scynexis' focus on antifungal treatments.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. offers antifungal and antiviral therapies, making it a competitor in the infectious disease market.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC has a portfolio that includes anti-infective drugs, competing with Scynexis in the pharmaceutical market.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments that compete with Scynexis' drug offerings.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie Inc. competes in the antifungal space with its own range of products, posing competition to Scynexis.
Novartis
NVS
Mkt Cap237.61B
Novartis AG engages in the development of drugs to treat a wide range of infections, including fungal, competing with Scynexis.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. has a diverse biopharmaceutical portfolio that includes treatments for infections, competing with Scynexis.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb has a range of anti-infective drugs, making it a competitor in the same market as Scynexis.
Sanofi
SNY
Mkt Cap124.45B
Sanofi operates in the pharmaceutical sector with a focus on anti-infectives among other areas, competing with Scynexis.

About

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Show more...
CEO
ISIN
US8112922005

Listings

XNAS
US
SCYX
F
DE
135A.F
LSE
GB
0L49.LSE
BOATS
BOATS
SCYX.BOATS

0 Comments

Share your thoughts

FAQ

What is Scynexis stock price today?▼
The current price of SCYX.BOATS is $0.88 USD — it has decreased by -0.43% in the past 24 hours. Watch Scynexis stock price performance more closely on the chart.
What is Scynexis stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Scynexis stocks are traded under the ticker SCYX.BOATS.
What is Scynexis market cap?▼
Today Scynexis has the market capitalization of 36.8M
When is the next Scynexis earnings date?▼
Scynexis is going to release the next earnings report on May 07, 2026.
What were Scynexis earnings last quarter?▼
SCYX.BOATS earnings for the last quarter are 0.25 USD per share, whereas the estimation was 0.13 USD resulting in a +97.37% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Scynexis revenue for the last year?▼
Scynexis revenue for the last year amounts to 7.49M USD.
What is Scynexis net income for the last year?▼
SCYX.BOATS net income for the last year is -42.58M USD.
When did Scynexis complete a stock split?▼
Scynexis has not had any recent stock splits.